Defining the Cut Point Between Low-grade and High-grade Ovarian Serous Carcinomas A Clinicopathologic and Molecular Genetic Analysis

被引：60

作者：

Ayhan, Ayse ^{[1
,2
,5
]}

Kurman, Robert J. ^{[1
,2
]}

Yemelyanova, Anna

Vang, Russell ^{[1
,2
]}

Logani, Sanjay ^{[3
]}

Seidman, Jeffrey D. ^{[4
]}

Shih, Ie-Ming ^{[1
,2
]}

机构：

[1] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA

[2] Johns Hopkins Med Inst, Dept Gynecol & Obstet, Baltimore, MD 21231 USA

[3] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA

[4] Washington Hosp Ctr, Dept Pathol, Washington, DC 20010 USA

[5] Seirei Mikatahara Gen Hosp, Dept Pathol, Hamamatsu, Shizuoka, Japan

来源：

AMERICAN JOURNAL OF SURGICAL PATHOLOGY | 2009年 / 33卷 / 08期

关键词：

ovarian cancer; serous carcinoma; grade; TP53; 2-tier grading system; MUTATIONS; PIK3CA; PATHWAYS;

D O I：

10.1097/PAS.0b013e3181a24354

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

A 2-tier grading system based on nuclear grade divides ovarian serous carcinomas into low (nuclear grade 1) and high grade (nuclear grade 3). In most instances the separation is straightforward but at times, the morphologic distinction between them can be difficult. We studied 11 ovarian serous carcinomas with features that were "intermediate" (nuclear grade 2) between low and high grade. All the cases were high staged and had a poor clinical outcome. None of the tumors showed mutations in KRAS, BRAF, and ERBB2 genes that characterize most low-grade serous carcinomas. In contrast, 10 (90.9%) of 11 cases contained nonsynonymous TP53 mutations characteristic of high-grade serous carcinomas. In summary, the molecular genetic profile and behavior of serous carcinomas with grade 2 nuclei are virtually the same as those of serous carcinomas with grade 3 nuclei, supporting the use of the 2-tier grading system for classifying ovarian serous carcinomas.

引用

页码：1220 / 1224

页数：5

共 19 条

[1]

[Anonymous], 1971, Acta Obstet Gynecol Scand, V50, P1

[2]

[Anonymous], 2003, PATHOLOGY GENETICS T

[3] Mutation of the PIK3CA gene in ovarian and breast cancer [J].